



## Mouse (monoclonal) Anti-Human B-cells, Carcinoma CD40

### PRODUCT ANALYSIS SHEET

<b>Catalog Number:</b>	AHS4002
<b>Lot Number:</b>	See product label
<b>Clone Number:</b>	EA-5
<b>Quantity/Volume:</b>	0.1 mg/0.1 mL
<b>Form of the Antibody:</b>	Purified immunoglobulin in phosphate buffered saline. Preservative-free and carrier-free. Filtered through a 0.22 µm filter. Purified from ascites.
<b>Preservation:</b>	None
<b>Isotype:</b>	IgG1
<b>Recognition:</b>	EA-5 immunoprecipitates proteins of 48 and 45 kDa. The 45 kDa band appears to be a degradative form of the larger protein.
<b>Specificity:</b>	<p>CD40 is expressed on peripheral blood and tonsillar B-cells, most B-cell lymphomas and leukemias, as well as several pre B-cell leukemias and some carcinomas. It is not present on most progenitor B-cell leukemias or terminally differentiated B-cells. The CD40 antigen shares structural homology with the nerve growth factor receptor. EA-5 competes for binding with the anti-CD40 monoclonal antibody G28-5 indicating similar epitope binding.</p> <p>Ligation of CD40 with this antibody causes decreased proliferation and up-regulation of IL-6 transcription with KTL-1 cells (Amo et al., 2000).</p>
<b>Applications:</b>	This antibody is suitable for use in immunoprecipitation and flow cytometry with utility in B-cell precursor development studies. Use approximately 1 µg to label $\leq 10^6$ cells for flow cytometry. The optimal antibody concentration should be determined for each specific application.
<b>Dilution</b> <b>Recommendations:</b>	Further dilutions should be made in medium or buffered solutions containing carrier protein, such as PBS with 0.1-1.0% BSA. Sodium azide (0.1%) may be added for long term storage of this product.
<b>Storage:</b>	Store at $\leq -20^\circ\text{C}$ . Upon initial thawing, apportion the antibody into working aliquots and store at $\leq -20^\circ\text{C}$ . Avoid repeated freeze/thaw cycles.

**For research use only. CAUTION: Not intended for human or animal therapeutic or diagnostic use.**

[www.invitrogen.com](http://www.invitrogen.com)

Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288 • E-mail: [techsupport@invitrogen.com](mailto:techsupport@invitrogen.com)

PI AHS4002

(Rev 06/09) DCC-09-0751

**Important Licensing Information** - These products may be covered by one or more Limited Use Label Licenses (see the Invitrogen Catalog or our website, [www.invitrogen.com](http://www.invitrogen.com)). By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

## References:

- Amo, Y., Y. Ohta, K. Katsuoka, and H. Tamauchi (2000) CD40 ligation inhibits trichilemmoma cell proliferation and induces IL-6 production. *J. Dermatol. Sci.* 22(2):124-131.
- Blauvelt, A., H. Asada, M.W. Saville, V. Klaus-Kovtun, D.J. Altman, R. Yarchoan, and S.I. Katz (1997) Productive infection of dendritic cells by HIV-1 and their ability to capture virus are mediated through separate pathways. *J. Clin. Invest.* 100(8):2043-2053.
- Goriely, S., B. Vincart, P. Stordeur, J. Vekemans, F. Willems, M. Goldman, and D. De Wit (2001) Deficient IL-12(p35) gene expression by dendritic cells derived from neonatal monocytes. *J. Immunol.* 166(3):2141-2146.
- Gruber, A., J.C. Wheat, K.L. Kuhen, D.J. Looney, and F. Wong-Staal (2001) Differential effects of HIV-1 protease inhibitors on dendritic cell immunophenotype and function. *J. Biol. Chem.* 276(51):47840-47843.
- Ismaili, J., J. Rennesson, E. Aksoy, J. Vekemans, B. Vincart, Z. Amraoui, F. Van Laethem, M. Goldman, and P.M. Dubois (2002) Monophosphoryl lipid A activates both human dendritic cells and T cells. *J. Immunol.* 168(2):926-932.
- Kawamura, T., M. Qualbani, E.K. Thomas, J.M. Orenstein, and A. Blauvelt (2001) Low levels of productive HIV infection in Langerhans cell-like dendritic cells differentiated in the presence of TGF-beta 1 and increased viral replication with CD40 ligand-induced maturation. *Eur. J. Immunol.* 31(2):360-368.
- Knapp, W., ed. (1989) *Leukocyte Typing IV*, Oxford University Press, London, pp: 91, 92, 153, 154, 203, 204.
- Larson, A., and T. LeBien (1994) Cross-linking CD40 on human B cell precursors inhibits or enhances growth depending on the stage of development and the IL costimulus. *J. Immunol.* 153:584.
- Law, C., B. Wormann, and T.W. LeBien (1990) Analysis of expression and function of CD40 on normal and leukemic human B cell precursors. *Leukemia* 4:732.
- Matasić, R., A.B. Dietz, and S. Vuk-Pavlović (2000) Cyclooxygenase-independent inhibition of dendritic cell maturation by aspirin. *Immunology* 101:53-60.
- Matasić, R., A.B. Dietz, S. Vuk-Pavlović (2001) Maturation of human dendritic cells as a sulfasalazine target. *Croatian Medical Journal* 42:44-445.
- Oravecz, T., G. Roderiquez, J. Koffi, J. Wang, M. Ditto, D. C. Bou-Habib, P. Lusso, and M.A. Norcross (1995) CD26 expression correlates with entry, replication and cytopathicity of monocytopathic HIV-1 strains in a T-cell line. *Nat. Med.* 1(9):919-926.
- Zavadova, E., C.A. Savary, S. Templin, C.F. Verschraegen, and R.S. Freedman (2001) Maturation of dendritic cells from ovarian cancer patients. *Cancer Chemotherapy and Pharmacology* 48(4):289-296.

**For research use only. CAUTION: Not intended for human or animal therapeutic or diagnostic use.**

[www.invitrogen.com](http://www.invitrogen.com)

Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288 • E-mail: [techsupport@invitrogen.com](mailto:techsupport@invitrogen.com)

PI AHS4002

(Rev 06/09) DCC-09-0751

**Important Licensing Information** - These products may be covered by one or more Limited Use Label Licenses (see the Invitrogen Catalog or our website, [www.invitrogen.com](http://www.invitrogen.com)). By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.